Biotechnology company Compass Pathways plc (Nasdaq: CMPS) announced on Wednesday that it has completed recruitment for its Phase 3 COMP005 trial investigating COMP360 psilocybin in treatment-resistant depression (TRD). Screening is now closed, with final participants undergoing pre-dosing procedures.

Top-line results for the trial's 6-week primary endpoint remain on track for late Q2 2025, with 26-week data expected following the completion of the COMP006 trial in the second half of 2026.

COMP360 is a synthetic psilocybin formulation designed for use with psychological support. The trial is the largest randomized, controlled, double-blind psilocybin study ever conducted.

Compass Pathways is focused on accelerating access to evidence-based innovations in mental health. COMP360 has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for TRD.